Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Gross Margin: 2012-2024

Historic Gross Margin for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to 51.08%.

  • Amphastar Pharmaceuticals' Gross Margin fell 189.00% to 51.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 49.36%, marking a year-over-year decrease of 362.00%. This contributed to the annual value of 51.08% for FY2024, which is 341.00% down from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Gross Margin of 51.08% as of FY2024, which was down 6.26% from 54.49% recorded in FY2023.
  • Amphastar Pharmaceuticals' 5-year Gross Margin high stood at 54.49% for FY2023, and its period low was 40.97% during FY2020.
  • For the 3-year period, Amphastar Pharmaceuticals' Gross Margin averaged around 51.81%, with its median value being 51.08% (2024).
  • In the last 5 years, Amphastar Pharmaceuticals' Gross Margin spiked by 465bps in 2021 and then crashed by 341bps in 2024.
  • Amphastar Pharmaceuticals' Gross Margin (Yearly) stood at 40.97% in 2020, then surged by 465bps to 45.63% in 2021, then surged by 425bps to 49.87% in 2022, then spiked by 462bps to 54.49% in 2023, then tumbled by 341bps to 51.08% in 2024.